Shah MA, Wainberg ZA, Catenacci DVT, Hochster HS, et al. Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib
(GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. PLoS One 2022;17:e0276211.
PMID: 36215283